Jeffrey D. Isaacson

Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Lecia V. Sequist, Jean‐Charles Soria, Jonathan W. Goldman et al. · New England Journal of Medicine · 2015 · 660 citations · Full text

<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza et al. · Cancer Discovery · 2018 · 403 citations

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer

Michael A. Carducci, Fred Saad, Per‐Anders Abrahamsson et al. · Cancer · 2007 · 292 citations

Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients

Dale J. Kempf, Jeffrey D. Isaacson, Martin King et al. · Journal of Virology · 2001 · 233 citations · Full text

Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics

Michael A. Carducci, Joel B. Nelson, M. Kathy Bowling et al. · Journal of Clinical Oncology · 2002 · 160 citations